STAT+: How biotech investors spot opportunity when stocks are down — and up
Following a blockbuster year of dealmaking and a recent uptick in biotech stocks, top investors…
Category: Pharma
STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, FDA syringe warnings, and more
And so, another working week will soon draw to a close. Not a moment too…
EU adviser says Illumina merger was not problematic
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Drug development was once a marathon. New tools and timelines are turning it into a sprint
Drug development is more of a sprint than a marathon these days, thanks to more…
STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, GSK asthma inhalers, and more
Top of the morning to you, and a fine one it is. Although quite chilly…
BioNTech is having its Pfizer moment
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharma companies and their allies seek to exempt orphan drugs from state pricing limits
As more states create dedicated boards to cap the costs of medicines, some drugmakers and…
STAT+: Pharmalittle: We’re reading about Europe’s pharma reform, weight-loss meds, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
Novo is building a really big computer
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: J&J sues former employee for allegedly taking thousands of documents to a new job at Pfizer
Johnson & Johnson has accused a long-standing employee of taking thousands of confidential files about…
Wegovy and Zepbound get primetime treatment
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about an AstraZeneca deal, a WHO pandemic pact, and more
Rise and shine, everyone, another busy day is on the way. Already, the official mascots…
STAT+: As targeted radiation field heats up, AstraZeneca to pick up Fusion Pharmaceuticals in $2 billion deal
LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more…
Contineum Therapeutics files for IPO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about CAR-T drugs for myeloma, CVS rebate credits, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about a liver-drug approval, pharma’s positive outlook, and more
And so, another working week will soon come to a close. Not a moment too…
What happens when an approved drug doesn’t work?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline
German pharmaceutical company Bayer is expanding its U.S. pharma business significantly, despite corporate turmoil and…
Virtual Event: March of the Biosimilars
Editor’s note: A livestream of this event will be embedded below at 1 p.m. ET….
Is CAR-T safe for early-stage patients?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: AstraZeneca picks up rare-disease focused Amolyt Pharma in $1 billion deal
LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal…
STAT+: BIO severs ties with WuXi in the face of U.S. government concerns over China
WASHINGTON — The Biotechnology Innovation Organization, an industry trade group, is cutting ties with Chinese…
STAT+: Pharma loses a key battle over a state law concerning 340B pharmacies
In a setback to the pharmaceutical industry, a U.S. appeals court has upheld an Arkansas…
STAT+: Pharmalittle: We’re reading about Amazon delivering Zepbound, hemophilia treatments, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
Geron’s resurgence might have been short-lived
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a failed schizophrenia drug trial, a Pfizer cancer drug, and more
Top of the morning to you, and a fine one it is. Sunny skies and…
When did Wall Street sour on Lilly’s Alzheimer’s drug?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Wegovy approved for heart risks, an ALS drug puzzle, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Preventing the weaponization of AI-designed proteins
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
STAT+: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label
U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its…
Eli Lilly’s anti-vanity ad campaign for Oscars
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Lilly Alzheimer’s drug adcomm, Amylyx ALS drug flop, and more
And so, another working week will soon draw to a close. Not a moment too…
Opinion: STAT+: It’s time to rethink everything about our approach to psychiatric drug development
In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed…
In his State of the Union, Biden takes clear aim at ‘Big Pharma’
WASHINGTON — Often, a president’s State of the Union address is a staid affair, with…
STAT+: Pharmalittle: We’re reading about a Lilly obesity-drug ad, a $35 cap on inhalers, and more
Rise and shine, everyone, another busy day is on the way. Moreover, this is shaping…
Banning WuXi is more complicated than it might sound
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Boehringer Ingelheim to cap asthma inhaler out-of-pocket costs at $35
Facing criticism over its pricing, Boehringer Ingelheim plans to cap out-of-pocket costs at $35 a…
.jpg)
Bayer’s not breaking up. At least not yet
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about HIV drug resistance, march-in rights, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: WTO proposal for Covid diagnostics and therapeutics waiver is abandoned
After 18 months of debate, the World Trade Organization failed to adopt a controversial proposal…
Where’s Lilly’s Alzheimer’s approval?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Ozempic tackling kidney disease, OTC birth control, and more
Good morning, everyone, and how are you today? We are doing just fine, despite a…
STAT+: Novo Nordisk’s diabetes drug Ozempic cuts risk of kidney disease progression, trial shows
LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney…
STAT+: White House is told the big three PBMs are ‘everything wrong with this industry’
As part of its battle to blunt the growing cost of medicines, the White House…
Serum Institute of India wants government HPV contract
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Opinion: Missing data is making it difficult for the pharmaceutical industry to help LGBTQ+ people
Lack of health data on LGBTQ+ people has real-world consequences. A participant in a 2020…
STAT+: Many costly generic drugs are unavailable at Amazon, Cuban, and other alternative pharmacies
A growing number of alternative pharmacies — such as those run by Costco, Amazon, and…
STAT+: Federal judge rules against AstraZeneca in lawsuit challenging Medicare drug price negotiation
WASHINGTON — A federal judge in Delaware on Friday ruled against AstraZeneca in a case…